University of Queensland spin-out Ceretas could be trading on the local bourse as early as next week after its initial public offering fetched strong demand. The medical technology firm, which develops portable ultrasound devices to treat brain conditions such as...
Scanning ultrasound to potentially treat Alzheimer's disease has been found to be safe and well tolerated in a first-in-human pilot study conducted by University of Queensland researchers.
Brisbane-based company Ceretas has been awarded a $2.4 million grant to fast-track development of its next-generation therapeutic ultrasound device - an Australian-designed innovation aiming to transform the treatment of Alzheimer’s disease.
Australian MedTech company Ceretas has successfully secured $1 million in seed funding to advance its low-cost, portable and non-invasive ultrasound device aimed at treating dementia and other neurological conditions.
Ceretas has officially licensed a groundbreaking ultrasound technology from The University of Queensland that offers a promising non-invasive treatment for Alzheimer’s disease. Developed by UQ researchers, this technology temporarily opens the blood-brain barrier to...